OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Friday, December 24, 2010

New Candidate Antibody-Drug Conjugate Gains Broad Patent Coverage - financial news (EGP-1 or TROP-2)




new quick patient poll on Blog - clear cell/Lynch Syndrome



Missed opportunity ?? - take the poll if you have been diagnosed clear cell/Lynch Syndrome

Boys who recorded charity song with Chris de Burgh are climbing the charts - Manchester Evening News




abstract: Hospital costs associated with adverse events in gynecological oncology (patient safety)



excerpts:

BACKGROUND AND OBJECTIVE: Treatment for gynecological malignancies is complex and may cause unintended or accidental adverse events (AE)....RESULTS: A total of 369 patients had surgical procedures of which 95 patients (26%) had at least one AE.

note Blogger's Comment/add yours - abstract: Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases (references Lynch Syndrome)



Blogger's comment/question: any other survivours (or not) of clear cell ovarian cancer and Lynch Syndrome NOT included in this study?  A missed opportunity.....

 note: absence of a direct reference to Lynch syndrome in abstract

 Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases.

*Department of Pathology, Memorial Sloan-Kettering Cancer Center ‡Department of Pathology, Vancouver General Hospital, NY †Department of Pathology, Massachusetts General Hospital, MA §Department of Pathology, University of Calgary, Calgary, Canada.

Abstract

Establishing a diagnosis of ovarian clear cell carcinoma (O-CCC) can be subject to significant interobserver variation. Accurately diagnosing this tumor is important because of its chemoresistance and reported association with Lynch syndrome. The spectrum of the morphologic features of O-CCC has not been well described in a series composed of immunohistochemically characterized cases. A total of 155 cases diagnosed as O-CCC were retrieved from the files of 3 institutions to analyze architectural and cytologic features. The immunohistochemical features of these cases have been reported earlier. A comprehensive list of features was recorded, including, but not limited to, architectural patterns, nuclear appearance, cytoplasmic characteristics, and mitotic index. Between 1 and 13 slides were available for review for each case. The cases were divided into 2 groups based on morphologic characteristics, those with features shared by the large majority (the first group, n=138) and those that showed unusual characteristics (second group, n=17). Tumors in the first group typically showed a mixture of architectural patterns, the most frequent being papillary and tubulocystic. Papillae, usually small and round and lacking hierarchical branching and tufting or stratification of more than 3 cells, were present at least focally in almost 3 of 4 cases. The cell shape was predominantly cuboidal, not columnar. Nuclear pleomorphism and prominent nucleoli were frequently present, but never diffusely. Clear cytoplasm was found in nearly every case and hobnail cells were common. Mitoses exhibited a range from 0 to 13 with an average of 3 to 4 per 10 high power fields. The second group of tumors showed numerous unusual morphologic characteristics, despite the presence of clear cytoplasm, including those typically seen in other ovarian epithelial tumors, such as serous and endometrioid carcinoma. Eighty-nine percent of tumors from the first group showed the expected "O-CCC immunophenotype" [hepatocyte nuclear factor (HNF) positive, and estrogen receptor (ER), progesterone receptor (PR), Wilms tumor 1 (WT1) and p53 negative], whereas 4% of tumors showed HNF positivity along with focal ER or PR expression. Seven percent of tumors were not immunoreactive with these markers. Twenty-nine percent of tumors in the second group showed the O-CCC immunophenotype, whereas 24% of tumors were p53 positive, 5% of tumors were WT1 positive, and the remaining cases were negative for all markers. Ninety-seven percent (112 of 117) of HNF-positive tumors in this series were classical O-CCC. Therefore, O-CCC has characteristic morphologic features and a specific, if not unique, immunophenotype in the vast majority of the cases. Clear cell-rich tumors with features that depart from the classical morphologic appearances described herein should suggest the possibility of an alternative diagnosis.

abstract: Histologic artifacts in abdominal, vaginal, laparoscopic, and robotic hysterectomy specimens: a blinded, retrospective review




Thursday, December 23, 2010

microRNA's - Revolutionizing Ovarian Cancer Treatment



"...That began to change earlier this decade as scientists discovered that microRNAs might actually be the hidden regulators that control the 30,000 genes in the human body by silencing gene expression.....One in particular, miR-31, discovered by Baylor collaborators and Gunaratne, shows promise as a potent tumor suppressor in ovarian cancer, glioblastoma, osteosarcoma and prostate cancer.......They discovered that miR-31 can specifically target and kill cancer cells that are deficient in p53, a crucial gene that guards the integrity of the genome and prevents cancer. More than half of all cancers and 90 percent of papillary serous tumors - the most common type of malignant ovarian cancer - are p53-deficient."

Do all contraceptives lower ovarian cancer risk? vasectomy ?? Reuters




Official NORAD Santa Tracker




The Spinoff (Part 4): No, Virginia, We Don’t Need More Innovation Conferences :: Longwoods.com




Reports of Serrated polyps of the colon - (references MSI/Lynch Syndrome) Mayo Clinic



Serrated polyps of the colon

Aravind Sugumar and Frank A Sinicrope
Division of Gastroenterology & Hepatology and Division of Oncology, Mayo Clinic and Mayo College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
Corresponding author
F1000 Med Reports2010, 2:89 (doi: 10.3410/M2-89)
Published: 17 Dec 2010
"....Among the more important findings is that SSAs may be the precursor lesions for MSI-H colon cancers. Furthermore, there is evidence that serrated polyps are more likely to be missed during colonoscopy [10,11,22]. As a result, colonoscopic follow-ups for serrated adenomas should be the same as for conventional adenomatous polyps...."

Wednesday, December 22, 2010

media: Monetary donations go a long way for families | Season for Caring (those stories of persons in great need)




A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence




Ovarian Cancer and Us - updated blog stats - just checking to see who's with us :-)



Pageviews today (9:53 am ET):
169
Pageviews yesterday:
269
Pageviews last month:
4,497
Pageviews all time history:
44,420

Why We Still Kill Patients: Invisibility, Inertia, And Income – Health Affairs Blog (re: patient safety movement....)



"......As Michael says, “There are no villains here.” Everybody means well. Unless assumptions like those above are explicitly exposed and challenged, though, another quotation might be apt: “The road to hell is paved with good intentions.”....

B.C. (British Columbia, Canada) tops in breast and ovarian cancer survival rates | media Vancouver re: Lancet article




abstract: The Impact of Age on the Treatment and Survival of Ovarian Cancer Patients



Purpose: Although a significant number of patients diagnosed with ovarian cancer are over the age of 65, these patients are less likely to receive standard therapy and are underrepresented in clinical studies. The objective of our study was to evaluate the treatment and survival of patients over the age of 65 years.

abstract: An Internet Survey of Symptoms Associated With Intra-Abdominal Malignancies: Lack of Specificity for Ovarian Cancer



Conclusion: This analysis fails to support the hypothesis that focusing attention on a pattern of nonspecific symptoms will be helpful in the diagnosis of ovarian cancer.

Scientists Discover Potential Strategy To Improve Cancer Vaccines




A Peer Review of Peer Review? | The Daily Scan | GenomeWeb




Tuesday, December 21, 2010

abstract/full access: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data : The Lancet



Note: Full access to article is free after registration (free)


"Background

Cancer survival is a key measure of the effectiveness of health-care systems. Persistent regional and international differences in survival represent many avoidable deaths. Differences in survival have prompted or guided cancer control strategies. This is the first study in a programme to investigate international survival disparities, with the aim of informing health policy to raise standards and reduce inequalities in survival.  

Methods Data from population-based cancer registries in 12 jurisdictions in six countries were provided for 2·4 million adults diagnosed with primary colorectal, lung, breast (women), or ovarian cancer during 1995—2007, with follow-up to Dec 31, 2007.

CBC News - Health - Cancer survival study 'good news' for Canada (small reference to ovarian cancer) including public comments



Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study : The Lancet Oncology



Interpretation

EPCAM deletion carriers have a high risk of colorectal cancer; only those with deletions extending close to the MSH2 promoter have an increased risk of endometrial cancer. These results underscore the effect of mosaic MSH2 deficiency, leading to variable cancer risks, and could form the basis of an optimised protocol for the recognition and targeted prevention of cancer in EPCAM deletion carriers.

media: Drug-Treatment Opportunities In Advanced Ovarian Cancer Will Be Limited By A Reduced Risk Of Disease Recurrence




Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations — J. Natl. Cancer Inst.



Note: some stats taken out for ease of reading

"...Among women with a BRCA1 mutation, the risk of breast cancer increased by 1.2-fold for each first-degree relative with breast cancer before age 50 years and the risk of ovarian cancer increased by 1.6 fold for each first- or second-degree relative with ovarian cancer ...cont'd

Cancer - NPCR - USCS - View Data Online - cancer stats U.S.



Note: ovarian cancer - 8th in incidence rate; 5th in death rate

How does he do it? Santa Claus (loved by all)




Court Backs Patents for Diagnostic Tests - NYTimes.com




Gauging Bill Gates’s Health Grants Five Years In - NYTimes.com



In an interview, Mr. Gates sounded somewhat chastened, saying several times, “We were naïve when we began.”....

Latest advances in medical oncology: highlights from Milan ESMO 2010 annual congress — Therapeutic Advances in Medical Oncology



new blog - Cancer Matters — Perspectives from those who live it everyday.




Donna J. Stecker Guest Book: sign their guest book, share your condolences, or read their obituary at The Washington Post




eHealthServer.com | European Commission Signs eHealth Agreement with US Department of Health



"...The partnership between the EU and the US, the two world leaders in eHealth, sends a strong signal to all stakeholders that common standards and interoperability bring opportunities for a global approach for the benefit of patients, health systems and the market"

Monday, December 20, 2010

Expert Commentaries: Promoting Transparent and Actionable Clinical Practice Guidelines: Viewpoint from the National Guideline Clearinghouse/National Quality Measures Clearinghouse (NGC/NQMC) Editorial Board



eg:

"..........The NGC/NQMC Editorial Board recommends avoiding vague or ambiguous recommendation statements (such as "Physicians may offer…" or "When possible…").

Recommendation statements containing vague or ambiguous language and expressions are not actionable, at least not consistently. This problem fosters subjective and potentially erroneous interpretation and thus can impede decision-making.

* Example:

  ..."Frequency of follow-up visits is based on the severity of disease presentation, etiology, and treatment.

Wide Genetic Testing for Lynch Syndrome Cost Effective online teleconference from AACR mp3 download Nov 18th, 2010



The American Association for Cancer Research hosted a teleconference on these findings on Thursday, Nov. 18, 2010, at 3:00 p.m. ET.
Download * the mp3 of the teleconference (10.5 MB, 46 minutes and 13 seconds)

*On a PC, right mouse click on the "Download" link and select "Save link as..." in Firefox or "Save Target as..." in Internet Explorer.

Patients Right to Know - Patient Safety U.S. - Transparency laws



The following states currently have some form of Transparency Law on the books:

Arizona
Georgia
New York
Texas
California
Idaho
North Carolina
Vermont
Colorado
Indiana
North Dakota
Virginia
Connecticut
Maryland
Oregon
West Virginia
District of Columbia
Massachusetts
Rhode Island

Florida
New Jersey
Tennessee



In Their Own Words: Susan Lowell Butler, Exec. Director DC Cancer Consor...



In Memory of: Susan Lowell Butler | Ovarian Cancer National Alliance




Salzburg Global Seminar - selected articles





Session Media:
Session Schedule
Session Directory

Activating Seniors to Improve Chronic Disease Care: Results from a Pilot Intervention Study (Dominick L. Frosch, David Rincon, Socorro Ochoa, and Carol M. Mangione)

Aligning Ethics with Medical Decision-Making: The Quest for Informed Patient Choice (Benjamin Moulton and Jaime S. King)

Communicating Evidence for Participatory Decision Making (Ronald M. Epstein, Brian S. Alper and Timothy E. Quill)

Helping Doctors and Patients Make Sense of Health Statistics (Gerd Gigerenzer, Wolfgang Gaissmaier, Elke Kurz-Milcke, Lisa M. Schwartz, and Steven Woloshin)

How Do US Journalists Cover Treatments, Tests, Products, and Procedures? An Evaluation of 500 Stories (Gary Schwitzer)

Implementing shared decision making in the NHS. (Glyn Elwyn and colleagues)

Improving productivity in the NHS. Reducing practice variation through better decision making is key (Albert Mulley) - [Article No. 5, if you scroll down the document]

Launching the Century of the Patient (Gerd Gigerenzer and J. A. Muir Gray)

Policy Support For Patient- Centered Care: The Need For Measurable Improvements In Decision Quality (Karen R. Sepucha, Floyd J. Fowler Jr., and Albert G. Mulley Jr.)

Reactions of Potential Jurors to a Hypothetical Malpractice Suit Alleging Failure to Perform a Prostate-Specific Antigen Test (Michael J. Barry, Pamela H. Wescott, Ellen J. Reifler, Yuchaio Chang, and Benjamin W. Moulton)

Rethinking Informed Consent: The Case for Shared Medical Decision- Making (Jaime Staples King and Benjamin Moulton)

Session Schedule

SHARED DECISION-MAKING IN THE MEDICAL ENCOUNTER: WHAT DOES IT MEAN? (OR IT TAKES AT LEAST TWO TO TANGO) by CATHY CHARLES, AMIRAM GAFNV and TIM WHELAN

The Future of Health Journalism (Gary Schwitzer)

The need to confront variation in practice (Albert G Mulley)

Clinicians' concerns about decision support interventions for patients facing breast cancer surgery options: understanding the challenge of implementing shared decision-making (Caldon LJ, Collins KA, Reed MW, Sivell S, Austoker J, Clements AM, Patnick J, Elwyn G; BresDex Group)
(http://www.ncbi.nlm.nih.gov/pubmed/21029281)

HEALTH CROSSROADS / HEALTH DIALOG: Prostate Cancer Screening
(https://www.healthcrossroads.com/example/crossroad.aspx?contentGUID=fc326615-5b29-47f1-87c3-9a3e2d946919)

HEALTH DIALOG: Getting the Healthcare That’s Right for You
(http://www.healthdialog.com/Main/Personalhealthcoaching/Shared-Decision-Making/Getting-The-Care-Thats-Right-For-You)

I Believe, Therefore I Do. (Frosch DL, Elwyn G.)
(http://www.ncbi.nlm.nih.gov/pubmed/21061083)

Implementing shared decision making in the NHS (Elwyn G, Laitner S, Coulter A, Walker E, Watson P, Thomson R.)
(http://www.ncbi.nlm.nih.gov/pubmed/20947577)

SESSION BLOG: e-Patient Dave: A Voice of Patient Engagement (Dave deBronkart)
(http://epatientdave.com/2010/11/29/a-radical-view-of-complianceadherence-from-1977/)

Session Position Paper - with thanks to the British Medical Journal: Do patients want a choice and does it work? by co-chair of the session, Angela Coulter, Director of Global Initiatives, Foundation for Informed Medical Decision Making
(http://www.bmj.com/content/341/bmj.c4989.full.html?ijkey=icrFYTXpKpvq5Bc&keytype=ref&siteid=bmjjournals)

TED: Sheena Iyengar on the art of choosing
(http://www.ted.com/talks/sheena_iyengar_on_the_art_of_choosing.html)

The New Yorker: The Cost Conundrum. What a Texas town can teach us about health care (Atul Gawande June 1, 2009)
(http://www.newyorker.com/reporting/2009/06/01/090601fa_fact_gawande?currentPage=all)

Tracking Medicine (John Wennberg)
(http://www.trackingmedicine.com/)

Abstract/free full access: What doctors think about the impact of managed care tools on quality of care, costs, autonomy, and relations with patients




Sunday, December 19, 2010



Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers — J. Natl. Cancer Inst.



Conclusion: Common genetic variation at the 9p22.2 locus was associated with decreased risk of ovarian cancer for carriers of a BRCA1 or BRCA2 mutation.

Genomics|Update|Current - Recommendation on Genetic Testing for Risk of Cardiovascular Disease



Recommendation on Genetic Testing for Risk of Cardiovascular Disease
 
This month the independent Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working GroupExternal Web Site Icon has released a new evidence-based recommendation on the use of “cardiogenomic profiles” (or “heart health”) genetic tests. These tests are being marketed to physicians and the general public as a way to find out a person’s risk for cardiovascular disease, and some can be ordered online without the involvement of a physician. The EGAPP Working Group did not find enough evidence to indicate whether these tests should or should not be used to determine future cardiovascular risk in the general population, and currently discourages the use of this testing except in research settings. Access the EGAPP recommendation.External Web Site Icon Read more about the EGAPP recommendation.

Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group



CONCLUSIONS: This combination was well tolerated and appears more active than the historical control of single agent taxane therapy in those with recurrent ovarian and peritoneal cancer after failing multiple lines of chemotherapy. Further study is warranted

Risk factors for recurrence of ovarian borderline tumors - abstract




Safety and tolerability of testosterone patch therapy for up to 4 years in surgically menopausal women receiving oral or transdermal oestrogen - abstr




Saturday, December 18, 2010

ImPatient For Change - blog (patient safety)




Nov 22, 2010 EDITORIAL The need for public engagement in choosing health - Canadian Medical Association Journal - December 17, 2010




full free access: PLoS Medicine: Which Path to Universal Health Coverage? Perspectives on the World Health Report 2010



Box 1. Key Recommendations of the World Health Report 2010

  • There is no single path or magic bullet to achieve universal health coverage: each country needs to devise its own route to achieve this goal.
  • All countries, but particularly poorer ones, need to reduce reliance on direct, out-of-pocket payments for health care by increasing risk pooling and prepayment for services.
  • Countries should address barriers to health care other than direct payments for care: transport costs and lost income can be substantial obstacles to care seeking.
  • There is substantial scope to raise further domestic resources for health care, particularly through innovative approaches to financing.
  • 20%–40% of health care expenditure is wasted; improved health system efficiency can make a substantial contribution to the achievement of universal health coverage.
  • Wealthier countries should provide financial support to low income countries in order for them to achieve universal health care coverage.
  • Despite some progress, development assistance for health remains fragmented and unpredictable; efforts to improve the efficiency and coordination of aid must be intensified.

new research: ICON7 Results May Change Practice in Ovarian Cancer | Cancer Survivors Network



OncologySTAT: Dr. Cervantes, what were the most important studies in ovarian cancer that were presented at this year’s ESMO Congress?

EvidenceUpdates: Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials - includes professional commentaries




Summary - Patupilone in cancer treatment




Nov 2010: Health Council of Canada / Conseil canadien de la santé - How Do Canadians Rate the Health Care System?









How Do Canadians Rate the Health Care System?

November 2010

Canadians visiting emergency departments for care, instead of seeing primary health care providers Health Council of Canada releases 2010 Commonwealth Fund International Health Policy Survey results.

full free access: Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology — JCO



Note: includes discussion on ovarian cancer (Avastin/disparities/screening)

Ovarian adenosarcoma arising from benign cystadenoma and associated intraoperative consultation pitfalls




Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening



Abstract

OBJECTIVE: In the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), ovarian cancer screening with transvaginal ultrasound (TVU) and CA-125 produced a large number of false-positive tests. We examined relationships between histopathologic diagnoses, false-positive test group, and participant and screening test characteristics.

CONCLUSIONS: False-positive ovarian cancer screening tests were associated with a range of histopathologic diagnoses, some of which may be related to patient and screening test characteristics. Further research into the predictors of false-positive ovarian cancer screening tests may aid efforts to reduce false-positive results.

The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review



CONCLUSION: Ultimately, serial imaging and the CA-125 assay detected the highest number of ovarian cancer and PCC progressive disease cases in comparison to physical examination and vaginal cytology, but nevertheless, all of the procedures were conducted at a considerable financial expense.

abstract: CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: A population-based study




Questioning the Role of CA125 as a Biomarker in Ovarian Cancer - Oncology Times




Mechanism of action and toxicities of purgatives used for colonoscopy preparation



Take home message: Although generally safe and effective, colonic purgatives have both acute and permanent toxicities. The safest preparations utilize PEG combined with a balanced electrolyte solution. Limitations of this preparation center on the volume required and poor taste. Alternative formulations are now available; however, those using sodium phosphate have fallen out of favor due to a risk of renal toxicity

Read More: http://informahealthcare.com/doi/abs/10.1517/17425255.2011.542411

Friday, December 17, 2010

HealthLinx Releases Initial Results from First Stage of 1,150-Subject OvPlex Study | ProteoMonitor | Proteomics | GenomeWeb




BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer



Abstract

Background: Neoadjuvant chemotherapy has shown a modest benefit in muscle-invasive bladder cancer patients; however, the subset of patients most likely to benefit has not been identified. BRCA1 plays a central role in DNA repair pathways and low BRCA1 expression has been associated with sensitivity to cisplatin and longer survival in lung and ovarian cancer patients.

Patients and methods: We assessed BRCA1 messenger RNA expression levels in paraffin-embedded pre-treatment tumor samples obtained by transurethral resection from 57 patients with locally advanced bladder cancer subsequently treated with neoadjuvant cisplatin-based chemotherapy. BRCA1 levels were divided into terciles and correlated with pathological response and survival....

"Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: Assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer.



CONCLUSIONS: At least half the cases of primary peritoneal high-grade serous carcinoma are associated with intraepithelial carcinoma of the fallopian tube, usually involving the fimbriae. These findings support the view that, like "primary ovarian carcinoma," what has been traditionally classified as "primary peritoneal carcinoma" is probably derived from occult high-grade serous carcinoma in the fallopian tube. These findings have important implications for ultrasound screening trials for ovarian cancer which are based on the assumption that an enlarged ovary is a very early manifestation of disease.

Ultrasound for Ovarian Cancer Screening: Are We Throwing the Baby out with the Bath Water? abstract




Echocardiographic imaging of tricuspid and pulmonary valve abnormalities in primary ovarian carcinoid tumor-abstract



Abstract

Carcinoid is a rare malignancy originating from enterochromaffin cells and is clinically characterized by flushing, diarrhea and bronchospasm, due to secretion of vasoactive substances. A dreaded complication is carcinoid heart disease, which mainly affects right cardiac chambers, resulting in thickened, immobile and retracted tricuspid and pulmonary valves. In the current report, a case of a 60-year old female presenting with symptoms of right heart failure is described. Transthoracic two-dimensional and real-time three-dimensional echocardiography findings, as well as biochemical markers, including pro-BNP and NT-pro-BNP, were consistent with carcinoid syndrome. The histological diagnosis of carcinoid was confirmed after surgical resection of an ovarian mass.

Handling ovarian cancer FIGO III-IV : evolution over the last 30 years - abstract (commentary/review?)



Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier sta



"....The association between common variants in BRCA1 and BRCA2 and risk of CBC may differ depending on BRCA1 and BRCA2 mutation carrier status."

Sex cord stromal tumors of the ovary in children - abstract (sertoli-leydig most aggressive cell type)



CONCLUSIONS: Completeness of resection and histology were important prognostic factors; in our series the Sertoli-Leydig Cell tumor was the most aggressive variety. Hormonal signs (precocious puberty, telarca, menarche) were common in younger patients and led to an early diagnosis. Cisplatin based chemotherapy seemed to be effective for locally advanced tumors.

An epidemic of loneliness : The Lancet (essay)




Clustering of concordant and discordant cancer types in Swedish couples is rare




Quality of pathology reports for advanced ovarian cancer: Are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial




2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours




Wednesday, December 15, 2010

Questions remain for more aggressive ovarian cancer screening | HemOncToday




Search of: ovarian cancer | Open Studies | Adult | received from 10/01/2010 to 12/15/2010 - List Results - ClinicalTrials.gov



Search of: ovarian cancer | Open Studies | Adult | received from 10/01/2010 to 12/15/2010 - List Results (34) - ClinicalTrials.gov

HealthLinx reports solid data from OvPlex study - ovarian cancer, medical diagnostics - Australian Life Scientist



Avastin: Key cancer-fighting (breast) drug on verge of being delisted by FDA - media



EGEN, Inc. Announces That Phase II Clinical Trial For Advanced Ovarian Cancer Is Open For Enrollment (IL-12)



"EGEN, Inc. announced that the first Phase II clinical trial utilizing EGEN-001 for the treatment of recurrent ovarian cancer is now open for enrollment. The trial is sponsored by the Gynecologic Oncology Group (GOG) under an agreement between the GOG and EGEN, Inc., and is being conducted by a network of researchers led by the GOG at member institutions. The University of Alabama at Birmingham (UAB) Hospital is the first member institution to open enrollment. Dr. Ronald Alvarez, of UAB Hospital, is the Study Chair for the trial. The GOG Principal Investigator at UAB Hospital is Dr. Mack Barnes....The product utilizes the Company's proprietary TheraPlas® delivery technology and is composed of interleukin-12 (IL-12) gene formulated with a biocompatible delivery polymer. IL-12 is a potent cytokine which works by enhancing the body's immune system against cancer and inhibiting tumor blood supply. We expect a number of the leading cancer centers in the U.S. to participate in this study and planning is underway to initiate additional Phase II trials in 2011, including the evaluation of EGEN-001 in treatment of colorectal cancer patients."...cont'd

Second Look at Estrogen in Breast Cancer Protection - NYTimes.com (re: WHI)



Blogger's Note: a similar issue was reported and largely ignored regarding colorectal cancer

“The data were absolutely missed. They weren’t emphasized, and they weren’t brought to the attention of oncologists,”...

Want fast care? Slip an MD some cash - media



abstract: (Lynch Syndrome) Analysis of EPCAM Protein Expression in Diagnostics of Lynch Syndrome ( -/+ MSH2)



NCI Cancer Bulletin: How to Strengthen Research Partnerships



NCI Cancer Bulletin: Statistical Strength in Numbers: International Clinical Trials for Rare Cancers



“International trials for rare cancers offer many advantages over separate trials done in different countries or regions,” explained Dr. Jack Welch of the Clinical Investigations Branch in NCI’s Cancer Therapy Evaluation Program (CTEP). “By bringing patients together, international trials can accrue faster, and they offer lower collective administrative costs, shared infrastructure, centralized resources, and use of existing networks.”.....On December 10, NCI and the American Society of Clinical Oncology (ASCO) convened a meeting of international stakeholders to explore ways to collaborate across borders on clinical trials for rare cancers. Nearly 100 representatives from 75 institutions participated in the day-long meeting, which was supported by CTEP, NIH’s Office of Rare Diseases Research (ORDR), NCI’s Office of Advocacy Relations (OAR), and ASCO. In addition to representatives from NIH, the FDA, the HHS Office for Human Research Protections, and NCI’s Clinical Trials Cooperative Group Program, attendees included investigators from Canada, France, Italy, Japan, Korea, the United Kingdom, the European Organisation for Research and Treatment of Cancer, and representatives of patient advocacy organizations and the pharmaceutical industry....cont'd

Level of Scientific Evidence Underlying Recommendations Arising From the National Comprehensive Cancer Network Clinical Practice Guidelines — JCO



Conclusion: Recommendations issued in the NCCN guidelines are largely developed from lower levels of evidence but with uniform expert opinion. This underscores the urgent need and available opportunities to expand evidence base in oncology.

Components of family history associated with women's disease perceptions for cancer: A report from the Family Healthware™ Impact Trial - abstract



PURPOSE: To determine the specific components of family history and personal characteristics related to disease perceptions about breast, colon, and ovarian cancers.

'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis



Abstract
PURPOSE OF REVIEW: To summarize the recent evidence for 'triple negative' epithelial ovarian cancer (TNEOC), characterized by lack of expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor type 2 (HER2), and to discuss its potential pathologic markers for prognosis and targeted therapy.
RECENT FINDINGS: 'Triple negative' phenotype is traditionally referred to as a specific subtype of breast cancer negative for estrogen receptor, progesterone receptor and HER2 expression. Recent studies have shown that such 'triple negative' phenotype also exists in ovarian and endometrial cancer. TNEOC accounts for about 15% of epithelial ovarian carcinoma. This specific subtype tends to exhibit more aggressive characteristics and a worse prognosis. The molecular features of TNEOC are similar to those of 'triple negative' breast cancer (TNBC), a widely studied histological subtype. Recently, a panel of specific pathologic biomarkers has been identified in TNBC. Currently, phase I and phase II trials to examine the safety and efficacy of a poly (ADP-ribose) polymerase inhibitor (olaparib) and angiogenesis inhibitors (sunitinib and bevacizumab) in TNBC are ongoing. These TNBC-associated pathologic markers could be used to screen for novel prognostic factors and therapeutic targets in TNEOC.
SUMMARY: 'Triple negative' phenotype has important implications for clinical management of patients with ovarian cancer.

abstract: Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells.



Abstract

The majority of patients with stage III/IV ovarian carcinoma that respond initially to standard therapies ultimately undergo relapse due to the survival of small populations of cells with tumor-initiating potential. These ovarian cancer-initiating cells (OCIC) are sometimes called cancer stem cells (CSC) since they express stem cell markers, and can survive conventional therapies such as chemotherapy, which usually target rapidly replicating tumor cells, and give rise to recurrent tumors that are more chemo-resistant and more aggressive. Thus it would be desirable to develop a therapy that could selectively target OCIC and be used to complement the conventional therapies. In the present study, we isolated a subset of ovarian cancer cells with a CD44(+) phenotype in samples from patients with ovarian cancer that possess CSC properties including the formation of spheroids in culture, self-renewal and the ability to be engrafted in immune-compromised mice. We next explored the use of immunotherapy using fusions of dendritic cells (DC) and OCIC to specifically target the OCIC sub-populations. Fusion cells prepared in this way activated T cells to express elevated levels of IFN-γ with enhanced killing of CD44(+) ovarian cancer cells. We envision a combined approach where conventional therapies such as chemotherapy kill the bulk of tumor cells, whereas OCIC-reactive CTL target the resistant OCIC fraction. A combined therapy such as this may represent a promising approach for the treatment of ovarian cancer.

Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.



Abstract

BACKGROUND: Pathologic and genetic data suggest that epithelial ovarian cancer may consist of indolent and aggressive phenotypes. The objective of the current study was to estimate the impact of a 2-phenotype paradigm of epithelial ovarian cancer on the mortality reduction achievable using available screening technologies.
CONCLUSIONS: The current analysis suggested that reductions in ovarian cancer mortality using available screening technologies on an annual basis are likely to be modest. A model that incorporated 2 clinical phenotypes of ovarian carcinoma into its natural history predicted an even smaller potential reduction in mortality because of the more frequent diagnosis of indolent cancers at early stages.

abstract: Aspiration cytology of ovarian cystic masses: histologic correlation and review of the literature.



Objective: To determine the diagnostic accuracy of cytologic evaluation of ovarian cystic masses.
Study Design: Sixty-seven ovarian cystic masses with fine needle aspiration cytology and concurrent or subsequent cystectomy/oophorectomy with histology were examined. Correlations with malignancy were made with 4 parameters: serum CA-125, radiographic size and architecture, and cytology.

Sunday, December 12, 2010

Tailored Cancer Care | Cleveland Clinic Health (focus on genetics/treatment options)



Uterine cancer screening effective, but not yet recommended – The Chart - CNN.com Blogs (Lynch Syndrome)



"..However Smith notes many postmenopausal women receive a late diagnosis because they overlook a very important warning sign. "The American Cancer Society places a great deal of emphasis of being aware that postmenopausal bleeding is not normal and if it occurs, contact a doctor immediately," he advises."

Monday, December 06, 2010

full free access: 2010 annual report published Dec 6th: Waiting Your Turn: Wait Times for Health Care in Canada - Fraser Institute



re: surgical/treatment related

Canada - Fraser Institute:The Dollar Cost of Medicare | Fraser Institute



The Dollar Cost of Medicare

Appeared in the New Brunswick Telegraph Journal
Authors:
Release Date: November 16, 2010
The true cost of Medicare for individuals and families in Canada is often misunderstood, with many people thinking it’s either free or covered by our provincial health insurance premiums....cont\d

Wednesday, December 01, 2010

Engaging Champions in Public Health Policy, Programming, and Practice



SUMMARY: A “champion” is a “charismatic advocate of a belief, practice,
program, policy and/or technology.”1 It is a champion’s unique combination
of skills—passion, persistence, and persuasiveness—that distinguish him
or her from other advocates. A 2007 Cochrane review concluded that the
use of opinion leaders can successfully promote evidence-based practices.2
Engaging influential opinion leaders can be an effective advocacy approach
for advancing social, economic, political, or public health issues.

full free access: Sex Hormones and Colorectal Cancer: What Have We Learned So Far? — J. Natl. Cancer Inst.




4th Evidence-based Complementary & Alternative Cancer Conference - Annie Appleseed project



This is our 4th Annual Evidence-based Complementary & Alternative Cancer Therapies conference, aka CAM for Cancer. Crowne Plaza Hotel, West Palm Beach, FL REGISTRATION IS OPEN until FEBRUARY 20 (because we have to have a count to order the ORGANIC food). Conference cost:$159 (includes 5 organic meals and 4 organic snacks)

HOTEL Rate is $120 per night and will hold for several days in advance and afterwards.

RESERVE a HOTEL Room Opens to a new page that goes directly to the hotel link for Annie Appleseed Project meeting.

Cancer Pain: An Age-Based Analysis - 2010 - Pain Medicine abstract



Wednesday, November 17, 2010

OncoMap Gene Sequencing Finds 50 Mutations in Ovarian Tumors : Internal Medicine News



".....The team, testing 203 samples with OncoMap, found mutations of 50 genes in total. Some mutations were in genes previously identified in ovarian cancer, including KRAS, CTNNB1, and PIK3CA. Others were not previously known to occur in this disease, but, importantly, are potential drug targets with existing agents. "It’s not like HER2 in breast cancer where that is found in about 30% of breast cancers – we found many mutations in the ovarian cancer samples and they were infrequent," Dr. Matulonis said in a telephone interview prior to the conference; she noted, however, that OncoMap identified KRAS and PIK3CA mutations as the most common, occurring in about 25% of tumors, and "that was reassuring," as it was in line with expectations..........Dr. Matulonis’ team is now using OncoMap on all new ovarian cancers, including nonserous cancers, diagnosed at Dana-Farber, and she predicted the test will become standard in clinical practice within 6 months to a year..........cont'd

(Halifax, NS) Immunovaccine Inc. Announces Phase I/II Clinical Plan for DPX-Survivac to Target Ovarian Cancer - MarketWatch



PARP (1 and 2) inhibitor, MK-4827, shows anti-tumor activity in first trial in humans (mutation/non mutation carriers)



"He gave a possible explanation as to why patients with cancers that were not caused by BRCA1/2 mutations also responded to the PARP inhibition. "BRCA is a tumour suppressor gene that assists in repairing double stranded DNA breaks. In BRCA-mutation related cancers, loss of both copies of the gene results in a non-functional protein and thus BRCA deficiency. Because BRCA works with other proteins, BRCA-pathway related deficiency can be seen in the absence of two mutated copies of the BRCA genes. This may explain why responses have been reported for this class of drugs in non-BRCA mutant cancers."

science article: Duke continues investigation as geneticist's work retracted (ovarian cancer patients to cisplatin drug therapy)




A prIME Oncology educational activity held after the official ESMO program hours: Evolving Strategies in the Management of Advanced Ovarian Cancer Oct



Topic 1—
Defining the rationale and role for targeted therapy in ovarian cancer
Nicoletta Colombo, MD
Topic 2—
Targeting angiogenesis: Where are we in 2010?
Robert A. Burger, MD, FACOG, FACS
Topic 3—
Beyond antiangiogenesis: What are the options?
Andres Poveda, MD


This Webcast contains video and downloadable slides from our symposium “Evolving Strategies in the Management of Advanced Ovarian Cancer,” a prIME Oncology educational activity that was held after the official ESMO program hours on Monday, 11 October in Milan, Italy.

Tuesday, November 16, 2010

Nov 16th: Wide Genetic Testing for Lynch Syndrome Cost Effective « AACR News telephone conference Nov 18th ET U.S./Canada



The American Association for Cancer Research will host a teleconference on these findings on Thursday, Nov. 18, 2010, at 3:00 p.m. ET. Reporters and other interested parties can participate by using the following information:

  • Dial-in (U.S. and Canada): (888) 282-7404
  • Dial-in (International): (706) 679-5207
  • Access Code: 20084557

Updated Oct 2010: Genetic Syndromes - Genetics of Breast and Ovarian Cancer - National Cancer Institute



Major Genes

Introduction


BRCA1
BRCA2
BRCA1 and BRCA2 Function


Mutations in BRCA1 and BRCA2
Variants of uncertain significance


Prevalence and Founder Effects


Models for Prediction of the Likelihood of a BRCA1 or BRCA2 Mutation


Penetrance of Mutations
Cancer risk in individuals who test negative for a known familial BRCA1/2 mutation
Breast and ovarian cancer risk in breast cancer families without detectable BRCA1/2 mutations


Population Estimates of the Likelihood of Having a BRCA1 or BRCA2 Mutation


Role of BRCA1 and BRCA2 in Sporadic Cancer


Genotype-Phenotype Correlations


Pathology/Prognosis of Breast Cancer
BRCA1
BRCA2
Contralateral breast cancer in BRCA mutation carriers

Pathology/Prognosis of Ovarian Cancer
Pathology
Prognosis

Other Rare Breast and Ovarian Cancer-Associated Syndromes
Li-Fraumeni syndrome
Cowden syndrome
Peutz-Jeghers syndrome

Families and Scientists Gather to Discuss Research and Treatment for Li-Fraumeni Syndrome



An archived video of the full meeting is available through the NIH Videocast Web site.

"...Li-Fraumeni syndrome was first described in a 1969 publication in the Annals of Internal Medicine by Dr. Joseph F. Fraumeni, Jr., the director of DCEG, and his colleague Dr. Frederick P. Li. They described four families in which several members developed a wide variety of cancers as children or young adults. Many of the patients had multiple primary tumors, most notably breast cancer, soft tissue and bone sarcomas, brain tumors, adrenocortical neoplasms, and acute leukemia. Subsequent studies identified additional families that met the classic criteria for LFS. Other families had similar but less pronounced aggregations of cancer and were classified as Li-Fraumeni-like (LFL)...."

(OVA1 ovarian cancer blood test) Vermillion Inks New Agreement with Quest Diagnostics - GLG News




Firm prepares for cancer patents hearing - The New Lawyer (BRCA patents) - Australia




Canary Foundation of Canada




Canary Foundation - Ovarian Cancer Program



Figure 1: Stage at Diagnosis Figure 2: Survival by Stage of Diagnosis

Expansion of cancer care and control in countries of low and middle income: a call to action : The Lancet



Note: includes a number of easy to read charts/comparisons

Editorial: Cancer: the revolution has begun : The Lancet




BRCA | prIME Oncology conference notice Tel Aviv, Israel Nov 18-19th




Advancing Ethical Research Conference - December 2010





abstract + Free Full-Text (2010) Familial Pancreatic Cancer (includes discussion regarding BRCA/Lynch Syndrome/FAMMM and others)



Abstract: Pancreatic cancer’s high mortality rate equates closely with its incidence, thereby showing the need for development of biomarkers of its increased risk and a better understanding of its genetics, so that high-risk patients can be better targeted for screening and early potential lifesaving diagnosis. Its phenotypic and genotypic heterogeneity is extensive and requires careful scrutiny of its pattern of cancer associations, such as malignant melanoma associated with pancreatic cancer, in the familial atypical multiple mole melanoma syndrome, due to the CDKN2A germline mutation. This review is designed to depict several of the hereditary pancreatic cancer syndromes with particular attention given to the clinical application of this knowledge into improved control of pancreatic cancer.
Keywords: phenotypic and genotypic heterogeneity; high mortality; genetic counseling; biomarker paucity; FAMMM syndrome; Li-Fraumeni syndrome; Lynch syndrome; pancreatic cancer

Management of Unexplained Symptoms in Survivors of Cancer — JOP abstract



M.R.I.’s Help Women at High Risk for Breast Cancer - NYTimes.com



Monday, November 15, 2010

press release: Australia - "FTY720" New treatment to overpower drug resistance in ovarian cancer



"Recent studies have also shown anti-tumour efficacy in several types of cancers but this is the first time it has been studied for the treatment of ovarian cancer."

New Therapies for Neuroendocrine Tumors (carcinoid tumors)



Note: Medscape requires (free) registration to view

Session Overviews Pharma-Nutrition 2011 Conference Netherlands conference notice/program



UK versus US health care: Atlantic rift : Editorial The Lancet



"Sadly, the political rancour about who spends what and on whom diverts attention from the real key to tackling chronic disease, and the only thing with the power to save both lives and money—disease prevention."

Women's Health in Asia | The Lancet Conferences Dec 2-5th announcement



a collection of videos: Ovarian Cancer - Cancer Health (including Ovarian Cancer and Our Pets - minus audio)



New test for ovarian cancer patients - RAD51 assay (UK)



Note: search blog for additional RAD51 information/studies

Margaret Polaneczky, MD - HRT Worries – This Time, It’s Ovarian Cancer Again…. | The Blog That Ate Manhattan (see simple charts)




Ovarian cancer drug shows promise with move to phase 3 trial (AMG 386) Clinical Oncological Society of Australia




Search of: ovarian cancer | Open Studies - List Results - ClinicalTrials.gov



Found 528 studies with search of: ovarian cancer | Open Studies

WORD on Cancer Team



Sunday, November 14, 2010

Abstract/full free access: Risk factors for perioperative venous thromboembolism (blood clots) : A retrospective study in Japanese women with gynecologic diseases




Surgical management of recurrent ovarian cancer: The advantage of collaborative surgical management and a multidisciplinary approach.



CONCLUSIONS: Previous studies document survival benefit of surgery for women with recurrent ovarian cancer when there has been a long disease-free interval, localized pelvic or intra-abdominal recurrences and an optimal performance status. Most gynecologic oncologists do not perform extensive liver or diaphragm resections or lymph node excision above the renal vessels; thus, collaboration with a surgical oncologist is a viable option. In this small descriptive study, the feasibility of this reasonably well-tolerated approach, with possible survival benefit, is documented.

Does the time interval between first and last birth influence the risk of endometrial and ovarian cancer?



CONCLUSION: Our findings suggest that the risk of endometrial cancer is significantly decreased for women having at least a difference of 10 years between their first and last birth. Ovarian cancer does not seem to be influenced by the time interval between first and last birth.

2011 full free access: Cancer Biology & Therapy Prognostic effect of epidermal growth factor receptor gene mutations and the aberrant phosphorylation of Akt and ERK in ovarian cancer




Antiproliferation effect of commercially brewed coffees on human ovarian cancer cells in vitro




The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer



Abstract

AIM: The objective of this study was to verify the impact of systematic retroperitoneal lymphadenectomy on survival in patients with ovarian cancer.
CONCLUSION: This study has demonstrated that the systematic lymphadenectomy had benefit only in patients with ovarian cancer macroscopically confined to the pelvis. In patients with clear cell adenocarcinoma, systematic lymphadenectomy was beneficial. To the contrary, systematic lymphadenectomy had no benefit on OS or PFS in patients with advanced ovarian cancer if optimally debulked.

full free access: Extraordinarily Prolonged Disease Recurrence in a Granulosa Cell Tumor Patient



Background
Granulosa cell tumors are rare sex cord stromal lesions that comprise approximately 3% of all ovarian neoplasms. The vast majority of granulosa cell tumors are considered indolent but in spite of aggressive management, delayed recurrence is of significant concern.
Conclusion
Granulosa cell tumors are considered to be of low malignant potential but they have the capacity to recur, even several years following initial patient management. This case exemplifies the disease's capacity for prolonged recurrence and further accentuates the significance of long-term follow-up in these patients.

Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor (negative study)




The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not effect progression-free or overal survival



Abstract

BACKGROUND.: Studies have suggested that erythropoietin-stimulating agents (ESAs) may effect progression-free survival (PFS) and overall survival (OS) in a variety of cancer types.

Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer



BACKGROUND: Sequential treatment with azacitidine can induce re-expression of epigenetically silenced genes through genomic DNA hypomethylation and reverse carboplatin resistance of epithelial ovarian cancer cells. A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.

Systemic chemotherapy--before (neoadjuvant) or after radical surgery in treatment of patients with advanced ovarian carcinoma?




Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary (case report)



Definition: Brenner tumours are uncommon tumours that are part of the surface epithelial-stromal tumour group of ovarian neoplasms

Synergistic Enhancement of Carboplatin Efficacy with Photodynamic Therapy in a Three-Dimensional Model for Micrometastatic Ovarian Cancer.




Impact of platinum-based chemotherapy on the progression of atherosclerosis



Definition: Atherosclerosis (also known as arteriosclerotic vascular disease or ASVD) is the condition in which an artery wall thickens as the result of a build-up of fatty materials such as cholesterol

Abstract/full free access: Population-based study of ovarian cancer in Cote d'Or (France): prognostic factors and trends in relative survival rates over the last 20 years




Consumption of dietary fat and meat and risk of ovarian cancer - the American Journal of Clinical Nutrition



Design: The NLCS includes 62,573 postmenopausal women, aged 55–69 y at baseline, who completed a baseline questionnaire on dietary habits and other risk factors for cancer in 1986. After 16.3 y of follow-up, 340 ovarian cancer cases and 2161 subcohort members were available for a case-cohort analysis. Multivariable rate ratios (RRs) were adjusted for age at baseline, total energy intake, oral contraceptive use, and parity

[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy.



Abstract

AIM: The most accepted standard duration of neoadjuvant chemotherapy (na-CHT) before debulking surgery for advanced ovarian cancer (AOC) is 3 courses. However a percentage of patients could benefit from additional courses......

Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer.




Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologists' expert meeting.




abstract: Opening the psychological black box in genetic couseling - impact uninformative result



Psychooncology. 2010 Nov 11. [Epub ahead of print]

Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.

 

 

Book Review - The Emperor of All Maladies - A Biography of Cancer - By Siddhartha Mukherjee - NYTimes.com




Tuesday, October 19, 2010

Comments | Decisions at the end of life: have we come of age? full free access - open for commentary





Decisions at the end of life: have we come of age?

Linda Emanuel email and Karen Glasser Scandrett email
BMC Medicine 2010, 8:57doi:10.1186/1741-7015-8-57


Blog addressing educational, research and genetics needs in ovarian cancer/related populations

(Commentary) Sandi Pniauskas (19 October 2010) Ovarian Cancer and Us email
Congratulations to the authors for addressing the issue of changing values and needs of patients at the close of life. Most North American studies on this topic err in their original suppositions regarding the preferred place of death. Generally the focus has been institutional and cost based as opposed to the values and ethics of yes, human dignity in dying. Specific to the needs of oncology patients/families, it is often disturbing to view reports asking citizens where they wish to die when we should know and understand that this answer cannot be of any value until those patients and families are 'in the moment'. The moment-to-moment changes in physical and emotional changes in cancer patients/families and all of the psycho-physio changes require that our systems adapt. Numerous real life examples of institutional/provider interference in the wishes of the dying are disturbingly unconscionable. The question which needs to be addressed is: 'Who's on 'first'?" Having witnessed circumstances where best practices were not followed in favour of cost analyses, we have to ask ourselves who will say no to money before suffering?
Competing interests
ovarian cancer survivor, Lynch Syndrome

Wednesday, October 13, 2010

Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna re: Survivors' Debate (Ovarian Cancer) - repost



Eye on DNA Exclusive Interview with Cancer Survivors Sandi Pniauskas and Carolyn Benivegna

by Dr. Hsien-Hsien Lei
Posted September 28, 2007 in DNA Testing, DNA and Disease, Personalities with DNA

How times have changed. Cancer has come from being taboo to being a subject of debate. Even better, ever more cancer survivors are now leading the charge for better healthcare.
Two ovarian cancer survivors, Sandi Pniauskas and Carolyn Benivegna, have joined to hold the Survivors Debate: The Past Decade in Ovarian Research. Two events are scheduled for October 27 in Michigan and November 3 in Toronto. Details are available at the Survivors Debate blog.
Earlier this week, Sandi and Carolyn participated in an exclusive interview with me for Eye on DNA. Learn more about what it’s like to have ovarian cancer and these women’s experiences with genetic testing. Their very personal stories remind us of the realities of cancer.
~~~~~
Hsien Lei: What is it like to have ovarian cancer as opposed to other forms of cancer?
carolynCarolyn Benivegna: Naturally, some forms of cancer are worse than others in terms of prognosis. I have no doubt that ovarian cancer will eventually kill me. I’m a fighter, though, and I keep beating it back with the biggest sticks I can find. I have been doing this for over nine years, though they said I probably wouldn’t live two years at the time of my diagnosis. Having ovarian cancer causes me to be angry at “the system” sometimes because ovarian cancer does not get its fair share of research funding or educational/awareness efforts. This has improved over the past decade, but it’s got a long way to go.
sandiSandi Pniauskas: This is an interesting question and indeed one which is very difficult to explain. I believe that most cancer patients/family caregivers might feel the same way at the time of the initial cancer diagnosis, so I will try to explain. I think the word ‘Cancer’ is first heard and then secondarily the type of cancer. As we know from public opinion polls, the vast majority of people do not necessarily understand that cancer is not a singular disease, but many different types and each one has its own set of treatments, prognosis and profile. People often ask what type of cancer, but after that, due to the lack of awareness and education, the detailed information does not ’stick’. Improvements in this area are being made, but it is my opinion, that we must change tactics because what we have been doing is not working for the vast majority.
I knew what ovaries were of course, but, had no idea that there was a cancer called ovarian cancer. Ovaries are indeed what makes women – women and this seems like such a rather insignificant statement . That is until we realize that not having ovaries (due to surgical intervention) makes a huge impact on the way we see ourselves, as women, not to speak of the complications which result and in particular premenopausal women, such as myself, due to surgical intervention. Similar to other cancers, it is not a cancer that you can ’see’, but not having ovaries, again, is not only biologically complex but emotionally as well. I guess I might try to equate this with cancer of the gall bladder. Trying to put this into context, as an example, may be gall bladder cancer patients and this is said with the greatest of respect for those patients. Patients, cancer or not, can live without a gall bladder but it is not typically associated with an extreme physical or emotional dysfunction.
With ovarian cancer comes the surprise that you don’t need to visit ‘that’ particular aisle of the drug store anymore. It’s a small issue in the larger picture, but part of every woman’s life. In fact, I think it took me 6 months to realize that the trek down this pharma aisle was no longer required. It’s a fact, which still to this day, strikes me with a small amount of humour. The larger less humourous issue is the lack of the ability to have children and while a select few ovarian cancers are spared, this is not the norm.
As to the broader question of other forms of cancer, I would have to say that now, when the words of ovarian cancer are mentioned, it brings a reaction of “Oh, that’s a bad one’” but on the other hand, often times, the general public believe that you take out the ovaries and get on with your life, along with maybe a little chemo. It is a sense of dismissal that is concerning and that indeed exists within our patient populations to some degree today. This is very concerning and very unfortunate.
Hsien: Sandi, you had a significant history of cancer in your family. How did that influence your approach to finding treatment for your own cancer?
Sandi: In fact, the realization came only after the fact in our situation. So, allow me to explain because it is important and sends a key message for the benefit of others.
When I was first diagnosed, and as the eldest of 5 siblings, I said I was ‘happy’ for the ovarian cancer diagnosis. Why ‘happy’? I thought, in a very uninformed way, that this meant that through my diagnosis I was ‘it’ for the family – that I had taken the ‘cancer hit’ for the family and so the others would be spared. In fact, 6 months and 1 year later two younger sisters also had cancer diagnoses. We were all in our ’40’s and 3 cancer diagnoses in a time span of 2 years, a fact which is quite stunning.
Since this time, I have come to realize that not only are we not alone, but indeed, there are worse families with many more incidents/deaths of cancers. After the diagnosis of cancer of the 3rd sibling, it dawned on me that something was not right. I remembered my Mother talking about her Grandmother and ‘being in bed all of the time because she was sick from cancer”. I pursued obtaining the medical death certificate for my Great-Grandmother and indeed, she died of colo-rectal and endometrial (uterine) cancers. My Grandfather also died of a cancer but I was unable to locate that information.
As with other families, there was no one still alive to ask for further information and this made it more challenging, but not insurmountable. The unfortunate part of all of this, in hindsight, is that it did not have to happen but it wasn’t necessarily the fault of anyone person, just the set of circumstances and timing. Unlike our situation, however, if there is any cancer diagnosis in the family it would be important to explore the family history right at the time of the initial diagnosis rather than letting it happen, so to speak. It might have saved my younger sister from her death, not to mention the suffering.
We are part of the genetic syndrome which is called the Lynch Syndrome and sometimes it is known as the ‘family cancer’ because of the wide range of cancers experienced in these families, ovarian cancer of which is one. Since I had already had my treatments, approach to treatment is an after-the-fact question. However, I had encouraged my younger sister to maintain a heightened surveillance program as her risk factors were the most similar to mine. At the time and before her diagnosis, I did not understand the connection and the risk for other cancers.
Would a heightened awareness and surveillance program have influenced her outcome? The answer at the very least is quite possibly.

teal ribbonHsien: Carolyn, do you also have a family history of cancer? How did this knowledge affect you?
Carolyn: Yes, my maternal grandmother died of breast cancer, my maternal grandfather died of stomach cancer, and my maternal aunt died of ovarian cancer. There was also some breast cancer on my father’s side of the family (two of his sisters). That’s why I was always conscientious about breast cancer screening, never dreaming that I was a candidate for ovarian cancer (having had my ovaries removed many years before my ovca diagnosis). After I was dx. with ovca, I insisted on genetic testing and was found to be BRCA-1 positive. Since then 12 other members of my family have been tested for that specific genetic mutation, and they are ALL positive.
The knowledge of the genetic mutation affected me by moving me into action to educate my family members about the genetic predisposition to the various cancers in the BRCA-1 mutation. It has also influenced my decisions on which treatments to take.
Hsien: How did you feel before, during, and after genetic testing (prior to receiving your results)?
Carolyn: I think I was generally numb before my genetic testing. I knew I had to do it, and I did it. I had been diagnosed, had surgery, and had two of six scheduled chemo treatments when I decided on genetic testing.
When I was found to be BRCA-1 positive, I was disappointed because it meant that my children were at risk due to something I had inadvertently passed on to them. Though I know I shouldn’t feel guilty about this, I can’t help feeling responsible for passing on something to them that could cause them a lot of pain and illness sometime in the future.
I’m glad I was tested, however, because I believe that knowledge gives us the power to make enlightened decisions about our healthcare. Prior to my diagnosis, I was not knowledgeable about ovarian cancer or genetic mutations and, consequently, was diagnosed at Stage IIIC Primary Peritoneal Cancer.
Sandi: I initiated the genetic testing for both the BRCA 1/2 and the Lynch Syndrome after our diagnoses. The rationale for the BRCA testing was due to unknown cancer types in our family, as well as a female first cousin, who was diagnosed with an early-age breast cancer. At this point, for me, the question was not what, but what to do with the information.
From a strictly scientific perspective and to bring research forward, I knew that genetic testing might one day bring a resolution to many of the unanswered questions and for the benefit of our future generations. So, I tried to look at this very clinically. Because I pursued the genetic testing after completing my treatments of surgery, chemotherapy and radiation, I had the benefit of time to reflect on the emotional issues. I often times try to convey to people that if we can, and it is not always possible, we need to put that emotional aspect in ‘a little box’. This is what I was able to do and this is strictly an individual response.
Not having had children also was of benefit because there was no burden of passing along those genes, which in my own personal set of circumstances made the genetic testing a much easier decision. If I had had children, the decision would have become much more complicated.
At the initial time of pursuing the genetic testing, I didn’t believe that waiting for the test results would be an issue. Understanding that while genetic testing in Canada is covered under our universal healthcare system, the results are not received in a timely manner. The results of the BRCA testing took 4 months and the results of the Lynch Syndrome testing took approximately a year. I kept myself very busy with ovarian cancer advocacy issues and participation in our international online community which is an easy way to say, I kept myself busy. However, not long after, I told the genetic counselor that while I thought waiting for the test results was not an issue, indeed, it was.
The BRCA results were negative which I anticipated. The Lynch Syndrome testing was ‘inconclusive’ meaning they were unable to locate anyone of the known genes. It is my belief that the only truly significant result is a positive result and while this stuns many people, to me a positive result means that there is some form of certainty and as a result there is a plan of action. An inconclusive result does not answer the question. Having said this, without a conclusive result, meaning a positive result, we are still faced with the reality of the family history and are waiting for science to catch up with us.
I do have to say that I am very encourage by new and recent research findings and while this does not necessarily, depending on the genetic syndrome, at this time, translate into day-to-day care, it will. After receiving the results, I am a firm advocate for awareness both within the healthcare professional communities and patient communities for the benefit of those who might be at risk for any familial link/cancer predisposition through a known genetic syndrome. It is important also for all cancer patients to understand that there are quite a number of different syndromes, so appropriate genetic counselling is crucial.
Hsien: After receiving the results of your genetic tests, how did you feel? How did the results influence your life choices?
Sandi: At this time, there are few options available for my future life choices. Surveillance and screening are available for only 2 of the cancers for which I am at risk. Fortunately, the highest risk for me at this point is colo-rectal cancer and there is screening available through colonoscopies. For those other cancers of which I am risk, there is no screening. However, we have taken care of endometrial and ovarian cancer risks due to my onset of ovarian cancer. While I am at a lesser risk for stomach and pancreatic cancers, I am hoping that those are not the ones which I will die from. At the same time, there continues to be the risk of a late/new ovarian cancer although small. Risk is all relative and risk is only low if it is not you – that’s the mind-game in all honesty.
Hsien: What do you think will be the hottest topics of the Survivors Debate? You specifically mention genetics and access to care and communications. How do your two viewpoints differ from one another? What do you hope people will do after attending the Debate?
Carolyn: I think one of the hottest topics will be “Access to Care.” This is a big issue in the U.S. right now and is a problem here and throughout the world. Sandi and I actually agree on many subjects. For the sake of the debate, we are taking opposing viewpoints on all the issues so that we can present diametrically opposite viewpoints, as a debate should!
I (personally) hope the debate will help create an environment where survivors will be included more in the dialog and decision-making processes as they pertain to cancer. I hope the controversy spurred by the debates will accelerate forums of this nature, resulting in increased research, treatment, and communication that includes survivors as the very core.
Sandi: One of the most important features of the Survivors’ Debate programs is that it allows, without bias or judgment, a public forum for people to express themselves through dialogue and indeed challenge the issues of what is not working. We know what is working, but we need to address what is not – publicly.
Personally, I am tired of doing the same-old, same-old. What always worries me is that many patients feel that by speaking up and out that this will impact their care. We must and need to change this sense of, in some cases a lack of entitlement, and it take a great deal of morale fortitude to do so. We encourage healthcare providers to attend en masse and also speak openly about their own issues. We want you to sit side by side with your patients – the human compassion and understanding which we will all take away with us will be the greatest and most successful and lasting result. It is also hoped that with public debate we can apply pressure for change. I have the belief and know that we can, but the question is will we?
There is a lot of anger amongst all of us, most of which is related to system failures. Today, we still have not been able to address the issues of the Patients voices in any effective way. Patients for the most part have the highest regard for their professional caregivers and want to have these dialogues. Fear of the unknown holds us back but it is decidedly less of a fear than the cancer itself, in my view. At the moment, other people are speaking for cancer patients and their families and we are at the point where the information is not being translated effectively.
The dichotomies in the medical literature attest to this where patients/family caregivers and medical staff do not have the same opinions on what is important. In fact, many healthcare professionals’ stories also note these issues. This is not so much of a criticism but a recognition of where we need to go. It is my profound expectation and hope that through these public forums we can bridge this gap. The debate forums allow us to take that much needed step forward, translating patients intellect and sense of responsibility and bring with it a public voice as opposed to a non-cancer voices in healthcare decision-making. If we do not do this, changes will occur which will not be effective in any meaningful way to those for whom we serve – the patients. This in fact, will be the change and from my perspective of mutual benefit to all.
On a personal level, I have lost not only family but most of the friends whom I first came into contact with when newly diagnosed. I simply cannot accept the degree of suffering which I experience each day, through others, without at least trying to take yes, a controversial but important step forward. These forums are not without controversy but we must put aside the issues which consistently get in the way of moving forward. I cannot think of a better or more humane way in which to do so.
Carolyn and I agree, as Carolyn mentions, on most issues. Most importantly ovarian cancer is a global issue and while some of the access to care are points of technical issues, the reality is that ovarian cancer to Carolyn and ovarian cancer to me, are the same. We both think this is extremely exciting that today patients are or can be the experts in their own cancers. If by chance, our information is lacking, then we want to know and we cannot underestimate how we truly believe this. An oncologist once told me that a little information is a dangerous thing. After initially being significantly annoyed, I decided he/she was right. These are our efforts to profile and dialogue what is not understood about the ‘average’ cancer patient but more important what is important. The learning curve has been steep, but it can be done.
The Debates are the mechanism to do so.
Thank you so much for allowing us to present our views, concerns and hopes for the future.
~~~~~
Bravo, Carolyn and Sandi! Thank you for sharing your stories and thoughts with us. There are many cancer survivors who will undoubtedly be inspired by your proactive determination.